NEKTAR THERAPEUTI…
USUSDNEKTAR THERAPEUTICS (LSE:0UNL) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 2. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- nektar.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- San Francisco, United States
- CEO
- Howard W. Robin
- Mitarbeiter
- 63
- Gegründet
- 1990
- Ausstehende Aktien
- 34.14 Mio. Stand 2026-08-07
- Streubesitz
- 28.28 Mio.
- Marktkapitalisierung
- 1.49 Mrd. USD
- Insider
- 0.38%
- Institutionelle Anleger
- 107.69%
- Branche (SIC)
- Pharmaceutical Preparations
- ISIN
- US6402683063
- LEI
- 5299005I24806IOIYE03
- FCF
- −234 Mio. USD
- Schulden
- 255 Mio. USD
- Gewinne und FCF – für die 12 Monate bis 30.06.2026 (aktueller Bericht des Unternehmens).
Beschreibung
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| FMR, LLC | 14.84% | 5.07 Mio. | 2026-06-30 |
| Two Seas Capital Lp | 9.06% | 3.09 Mio. | 2026-06-30 |
| Blackrock Inc. | 8.62% | 2.94 Mio. | 2026-06-30 |
| BVF Inc. | 7% | 2.39 Mio. | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 5.36% | 1.83 Mio. | 2026-07-31 |
| Vanguard Capital Managem… | 4.38% | 1.5 Mio. | 2026-06-30 |
| Two Sigma Investments, L… | 3.52% | 1.2 Mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.15% | 1.08 Mio. | 2026-06-30 |
| Vestal Point Capital, LP | 2.93% | 1 Mio. | 2026-06-30 |
| Morgan Stanley | 2.74% | 936 560 | 2026-06-30 |
| State Street Corporation | 2.66% | 909 679 | 2026-06-30 |
| iShares Trust-iShares Ru… | 2.59% | 882 671 | 2026-08-31 |
| Geode Capital Management… | 2.58% | 881 306 | 2026-06-30 |
| Fidelity Mt. Vernon Stre… | 1.45% | 495 043 | 2026-07-31 |
| Fidelity Mt. Vernon Stre… | 1.23% | 419 823 | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 1.14% | 387 571 | 2026-06-30 |
| Fidelity Salem Street Tr… | 1.1% | 376 892 | 2026-07-31 |
| iShares Trust-iShares Ru… | 0.85% | 289 533 | 2026-08-31 |
| PRIMECAP Odyssey Funds-P… | 0.5% | 172 419 | 2026-07-31 |
| Fidelity Concord Street… | 0.49% | 166 577 | 2026-07-31 |
| ROBIN HOWARD W (Chief Ex… | ≈0.16% | 54 655 | 2026-08-18 |
| WILSON MARK ANDREW (Offi… | ≈0.06% | 21 585 | 2025-11-25 |
| ZALEVSKY JONATHAN (Offic… | ≈0.03% | 9 570 | 2026-08-18 |
